W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

MS4A1

MS4A1

Overview

MS4A1 encodes CD20, a B-cell surface protein that is widely used as a lineage marker in immunology and hematologic oncology. CD20 is expressed on mature B cells and is absent from most other normal tissues, which has made it an important biomarker and therapeutic target in B-cell malignancies and immune-mediated diseases. In biomedical research, MS4A1 is commonly used to identify B-cell populations, assess B-cell depletion, and evaluate antigen expression patterns in lymphoma and related settings.

Functionally, CD20 is best known as a cell-surface target for antibody-based therapies and engineered cellular immunotherapies. Because it is retained on many malignant B cells, MS4A1/CD20 has become central to strategies such as anti-CD20 antibodies, CD20-directed CAR-T cells, and tandem or bispecific CD19/20 approaches designed to reduce antigen escape. Recent studies also use CD20 in spatial transcriptomic profiling to define B-cell and plasma cell-like phenotypes within the tumor microenvironment.

Focus of Latest Publications

Recent publications continued to position MS4A1/CD20 as a key marker and therapeutic target in B-cell non-Hodgkin lymphoma, especially diffuse large B-cell lymphoma (DLBCL) and relapsed/refractory B-cell malignancies. In a spatial transcriptomics study of DLBCL, researchers profiled distinct plasma cell-like phenotypes using combinations of CD20, HLA-DRA, and PRDM1. The reported phenotypes included CD20+HLA-DRA+PRDM1-, CD20+HLA-DRA+PRDM1+, CD20+HLA-DRA-PRDM1-, and CD20+HLA-DRA-PRDM1+, showing that CD20 remained detectable across multiple transcriptionally defined states and could be used to resolve heterogeneity within plasma cell-like tumor compartments.

Several studies focused on CD20-directed immunotherapy. A Science Advances report on CD20 EryPatch described a red blood cell patch designed to adhere to B cells and anchor on CD20 receptors across extensive cell-surface areas, supporting enhanced B-cell depletion therapy. This work highlights CD20 as a surface anchor for targeted delivery systems. In parallel, a clinical immunotherapy study of relapsed or refractory B-cell non-Hodgkin lymphoma reported spatial transcriptomic profiles from CD19/20 CAR-T therapy, emphasizing that dual targeting of CD19 molecule and CD20 may help mitigate antigen loss, a known mechanism of resistance in B-cell malignancies.

A related preclinical study of zamtocabtagene autoleucel described a first-in-human phase 1 trial of a noncryopreserved tandem CD20-CD19-directed CAR T-cell therapy. The rationale was to reduce selective pressure on CD19 by incorporating CD20 targeting, again underscoring the importance of MS4A1 in combination antigen strategies. Another preclinical report on next-generation CD179a-CAR-T cells noted that conventional CAR constructs targeting CD19 or CD20 can cause off-tumor toxicity because these antigens are shared on healthy B cells, reinforcing the need to balance efficacy with B-cell depletion-related safety concerns.

In a multi-omics study of Danggui Buxue decoction in benzene-induced blood deficiency syndrome, the immune microenvironment was reported to be remodeled by enhancing MHC class II antigen presentation and immune cell activation, including CD20 among other markers such as CD22, CD37, and CD8a. Although CD20 was not the primary therapeutic target in that study, its inclusion reflects its continued use as a B-cell activation and lineage marker in immune restoration analyses. Overall, these studies show that MS4A1/CD20 remains central both as a diagnostic marker for B-cell states and as a therapeutic target in cancer immunotherapy.

Key Publications

  • Jun Digital spatial profiling uncovers transcriptomic features of distinct plasma cell-like phenotypes in diffuse large B-cell lymphoma. (Blood advances, 2026, PMID 41886633): "Using spatially resolved transcriptomics, we profiled 4 distinct plasma cell-like phenotypes in DLBCL based on CD20, HLA-DRA, and PR domain zinc finger protein 1 (PRDM1) markers: CD20+HLA-DRA+ PRDM1-, CD20+ HLA-DRA+ PRDM1+, CD20+ HLA-DRA-PRDM1-, and CD20+ HLA-DRA-PRDM1+."
  • Jun Quality Evaluation, Antioxidant Capacity Assessment, and Environmental Correlations of Sinopodophyllum hexandrum From Different Origins Based on Multi-Indicator Quantitative Analysis. (Biomedical chromatography : BMC, 2026, PMID 42080542): "Notably, antioxidant capacity correlated significantly with B1 (precipitation supply capacity and temperature fluctuation stability), and quercetin was the most environment sensitive component."
  • Jun Novel PVA/collagen composite films loaded with 2-hydroxychalcones for controlled drug delivery and biomedical applications. (International journal of biological macromolecules, 2026, PMID 42097433): "Films containing B1 exhibited a faster release rate."
  • Jun Microbial Dynamics During the Anaerobic Digestion of Raw Sewage and Electro-Flocculated Wastewater for Biohydrogen and Biomethane Production using Synthetically Designed Microbial Consortia. (Water environment research : a research publication of the Water Environment Federation, 2026, PMID 42206807): "Three different heat-pretreatment consortia and their untreated counterparts were tested in two AD batch experiments (B1 and B3)."
  • May Multi-omics analysis reveals that Danggui Buxue decoction ameliorates benzene-induced blood deficiency syndrome via the restoration of hematopoietic lineage and remodeling of the immune microenvironment. (Chinese medicine, 2026, PMID 42174699): "On the other hand, it reshapes the immune microenvironment by enhancing MHC class II antigen presentation (e.g., H2Aa, H2-Ab1, H2-DMb1, and H2-Eb1) and immune cell activation (e.g., CD22, CD37, CD20, and CD8a), thereby reestablishing immune homeostasis."
  • May Erythrocyte patch for enhanced B cell depletion therapy. (Science advances, 2026, PMID 42160424): "CD20 EryPatches are designed to adhere to B cells and anchor on CD20 receptors across extensive cell surface areas."
  • May Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma. (Journal for immunotherapy of cancer, 2026, PMID 42144261): "Dual targeting of CD19 and CD20 may mitigate antigen loss."
  • Apr Next-generation CD179a-CAR-T cells demonstrate potent and sustained anti-tumor activity in preclinical B-cell malignancies. (Molecular biology reports, 2026, PMID 42047877): "However, conventional CAR constructs targeting CD19 or CD20 often result in off-tumor toxicity due to shared antigen expression on healthy B-cells."
  • Apr Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial. (Blood advances, 2026, PMID 41512222): "To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phase 1 clinical trial of zamtocabtagene autoleucel (zamto-cel), a noncryopreserved tandem CD20-CD19-directed CAR T-cell therapy."
Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.